tiprankstipranks
Trending News
More News >
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
US Market

Enanta Pharmaceuticals (ENTA) Income Statement

Compare
190 Followers

Enanta Pharmaceuticals Income Statement

Last quarter (Q3 2025), Enanta Pharmaceuticals's total revenue was $18.31M, an increase of 1.91% from the same quarter last year. In Q3, Enanta Pharmaceuticals's net income was $-18.25M. See Enanta Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 25Dec 24Dec 23Dec 22
Total Revenue
$ 65.32M$ ―$ 67.64M$ 79.20M$ 86.16M
Gross Profit
$ 65.32M$ ―$ 67.64M$ 79.20M$ 86.16M
Operating Expenses
$ 150.67M$ ―$ 189.33M$ 216.41M$ 210.00M
Depreciation and Amortization
$ 5.09M$ ―$ 2.34M$ 2.37M$ 2.97M
EBITDA
$ -70.78M$ ―$ -104.51M$ -123.48M$ -119.22M
Operating Income
$ -85.35M$ ―$ -121.69M$ -137.21M$ -123.84M
Other Income/Expenses
$ 1.80M$ ―$ 3.90M$ 6.21M$ 1.66M
Pretax Income
$ -83.55M$ ―$ -117.79M$ -131.00M$ -122.19M
Net Income
$ -81.89M$ ―$ -116.05M$ -133.82M$ -121.75M
Per Share Metrics
Basic EPS
$ -3.84$ ―$ -5.48$ -6.38$ -5.91
Diluted EPS
$ -3.84$ ―$ -5.48$ -6.38$ -5.91
Weighted Average Shares Outstanding
21.34M 21.16M 20.97M 20.60M
Weighted Average Shares Outstanding (Diluted)
21.34M 21.16M 20.97M 20.60M
Currency in USD

Enanta Pharmaceuticals Earnings and Revenue History